L
Liza A. Vergara
Researcher at University of Queensland
Publications - 21
Citations - 1571
Liza A. Vergara is an academic researcher from University of Queensland. The author has contributed to research in topics: Randomized controlled trial & Pentoxifylline. The author has an hindex of 8, co-authored 17 publications receiving 1446 citations.
Papers
More filters
Journal ArticleDOI
An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival
Lance D. Miller,Johanna Smeds,Joshy George,Vinsensius B. Vega,Liza A. Vergara,Alexander Ploner,Yudi Pawitan,Per Hall,Sigrid Klaar,Edison T. Liu,Jonas Bergh +10 more
TL;DR: The p53 signature identified a subset of aggressive tumors absent of sequence mutations in p53 yet exhibiting expression characteristics consistent with p53 deficiency because of attenuated p53 transcript levels, showing the primary importance of p53 functional status in predicting clinical breast cancer behavior.
Journal ArticleDOI
Antibacterial honey for the prevention of peritoneal-dialysis-related infections (HONEYPOT): a randomised trial
David W. Johnson,David W. Johnson,David W. Johnson,Sunil V. Badve,Sunil V. Badve,Elaine M. Pascoe,Elaine Beller,Alan Cass,Carolyn Clark,Janak de Zoysa,Janak de Zoysa,Nicole M. Isbel,Nicole M. Isbel,Steven McTaggart,Alicia T. Morrish,E. Geoffrey Playford,E. Geoffrey Playford,Anish Scaria,Paul Snelling,Paul Snelling,Liza A. Vergara,Carmel M. Hawley,Carmel M. Hawley +22 more
TL;DR: The findings of this trial show that honey cannot be recommended routinely for the prevention of peritoneal-dialysis-related infections.
Journal ArticleDOI
The β-Blocker to Lower Cardiovascular Dialysis Events (BLOCADE) Feasibility Study: A Randomized Controlled Trial
Matthew A Roberts,Helen Pilmore,Francesco L. Ierino,Sunil V. Badve,Alan Cass,Amit X. Garg,Nicole M. Isbel,Henry Krum,Elaine M. Pascoe,Vlado Perkovic,Anish Scaria,Andrew Tonkin,Liza A. Vergara,Carmel M. Hawley +13 more
TL;DR: Recruiting patients receiving dialysis to an RCT of β-blocker versus placebo will prove challenging and possible solutions include international collaboration and exploring novel trial designs such as a registry-based RCT.
Journal ArticleDOI
A tRial Evaluating Mid Cut-Off Value Membrane Clearance of Albumin and Light Chains in HemoDialysis Patients: A Safety Device Study.
Rathika Krishnasamy,Carmel M. Hawley,Meg Jardine,Matthew A Roberts,Yeoungjee Cho,Muhgeot Wong,Anne Heath,Craig Nelson,Shaundeep Sen,Peter F Mount,Elaine M. Pascoe,Liza A. Vergara,Peta-Anne Paul-Brent,Nigel D Toussaint,David W. Johnson,Colin A. Hutchison +15 more
TL;DR: Regular HD using the MCO dialyzer did not result in a significant fall in serum albumin and there was no improvement in restless legs symptoms, quality of life, 6MWT or MIS scores.
Journal ArticleDOI
A Randomized, Placebo-Controlled Trial of Pentoxifylline on Erythropoiesis-Stimulating Agent Hyporesponsiveness in Anemic Patients With CKD: The Handling Erythropoietin Resistance With Oxpentifylline (HERO) Trial
David W. Johnson,David W. Johnson,David W. Johnson,Elaine M. Pascoe,Sunil V. Badve,Sunil V. Badve,Kim Dalziel,Alan Cass,Philip Clarke,Paolo Ferrari,Paolo Ferrari,Stephen P. McDonald,Stephen P. McDonald,Alicia T. Morrish,Eugenie Pedagogos,Eugenie Pedagogos,Vlado Perkovic,Donna Reidlinger,Anish Scaria,Rowan G. Walker,Rowan G. Walker,Liza A. Vergara,Carmel M. Hawley,Carmel M. Hawley +23 more
TL;DR: Pentoxifylline did not significantly modify ESA hyporesponsiveness, but increased hemoglobin concentration, and the overall economic impact over the trial period was a saving of A$1,244 (US $1,172) per person for the pentoxifyLLine group compared with controls.